CLAUDIN-6 TARGETING MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF

Title:

CLAUDIN-6 TARGETING MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF

Document Type and Number:

WIPO Patent Application WO/2021/200939

Kind Code:

A1

Abstract:

The present disclosure provides multispecific antigen-binding molecules capable of binding to CD3 and CD137 (4-1BB) but not binding to CD3 and CD137 at the same time, and capable of binding to CLDN6. The multispecific antigen-binding molecules of the present disclosure exhibit enhanced T-cell dependent cytotoxicity activity in a CLDN6-dependent manner through binding to the CD3/CD37 and CLDN6. The present invention provides multi-specific antigen-binding molecules and pharmaceutical compositions thereof that can be used for targeting cells expressing CLDN6, for use in immunotherapy for treating various cancers, especially those associated with CLDN6 such as CLDN6-positive cancers.

More Like This:

WO/2021/018168	ANTI-BCMA ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF
JP2023071979	VSIG8-BASED CHIMERIC PROTEINS
JP2008156359	ALK-7 (ACTIVIN-LIKE KINASE), SERINE THREONINE KINASE RECEPTOR

Inventors:

ISHII SHINYA (JP)
KIMURA NAOKI (JP)
KODAMA TATSUSHI (JP)

Application Number:

PCT/JP2021/013526

Publication Date:

October 07, 2021

Filing Date:

March 30, 2021

Export Citation:

Click for automatic bibliography generation Help

Assignee:

CHUGAI PHARMACEUTICAL CO LTD (JP)

International Classes:

C07K16/28; C07K16/44; C07K16/46

Domestic Patent References:

WO2019111871A1	2019-06-13
WO2014075697A1	2014-05-22
WO2019135404A1	2019-07-11

Other References: